Participants:18–64 years · 65+ years
Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Registered drugNo placebo

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Azacitidine

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Investigational

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Resmetirom

Contact Research Centre

Chronic kidney disease

Not recruiting

Registered drug

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Balcinrenone

Contact Research Centre

Breast cancer+2

Not recruiting

Registered drugNo placebo

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Immune thrombocytopenia

Not recruiting

Registered drug

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Eltrombopag

Contact Research Centre

Colitis ulcerative

Not recruiting

Registered drugNo placebo

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Risankizumab

Contact Research Centre

Multifocal motor neuropathy

Not recruiting

Registered drug

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Empasiprubart

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Interstitial lung disease+1

Not recruiting

Investigational

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol

Contact Research Centre

Find therapies in clinical trials near you – page 4

88 trials match your criteria

Plasma cell myeloma refractory

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Non-small cell lung cancer

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

Acute myeloid leukaemia

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Metabolic dysfunction-associated steatohepatitis+1

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Chronic kidney disease

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Breast cancer+2

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Immune thrombocytopenia

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Colitis ulcerative

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Multifocal motor neuropathy

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Hormone receptor positive HER2 negative breast cancer

Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

Interstitial lung disease+1

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.